Artificial cell

ACM Biolabs Further Strengthens Leadership, Appoints David Lawrence to Board of Directors

Retrieved on: 
Tuesday, April 11, 2023

Madhavan Nallani, Chief Executive Officer of ACM Biolabs, commented: "We are delighted to welcome David to the team at this critical point in the development of our ATP™ technology.

Key Points: 
  • Madhavan Nallani, Chief Executive Officer of ACM Biolabs, commented: "We are delighted to welcome David to the team at this critical point in the development of our ATP™ technology.
  • I look forward to working closely with him as we progress with our partnering and accelerate the growth of ACM Biolabs."
  • David Lawrence said: "I am thrilled to be joining ACM at this exciting time in their development, to expand the possibilities of their novel polymer-based platform.
  • I look forward to working with Madhavan, the Board and the team to help unlock the potential of ACM and their unique technology."

ACM Biolabs Further Strengthens Leadership, Appoints David Lawrence to Board of Directors

Retrieved on: 
Tuesday, April 11, 2023

Madhavan Nallani, Chief Executive Officer of ACM Biolabs, commented: "We are delighted to welcome David to the team at this critical point in the development of our ATP™ technology.

Key Points: 
  • Madhavan Nallani, Chief Executive Officer of ACM Biolabs, commented: "We are delighted to welcome David to the team at this critical point in the development of our ATP™ technology.
  • I look forward to working closely with him as we progress with our partnering and accelerate the growth of ACM Biolabs."
  • David Lawrence said: "I am thrilled to be joining ACM at this exciting time in their development, to expand the possibilities of their novel polymer-based platform.
  • I look forward to working with Madhavan, the Board and the team to help unlock the potential of ACM and their unique technology."

PharmaCyte Biotech Successfully Completes 1 Year Stability Study

Retrieved on: 
Thursday, April 1, 2021

The study will continue in order to determine the maximum shelf life of the CypCaps product.

Key Points: 
  • The study will continue in order to determine the maximum shelf life of the CypCaps product.
  • As reported previously, the ongoing stability study is designed to determine the shelf life of the Cell-in-a-Box encapsulated cell product, CypCaps, stored frozen at -80oC.
  • PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box.
  • More information about PharmaCyte Biotech can be found at www.PharmaCyte.com .

PharmaCyte Biotech Appoints Cellular Expert to Medical and Scientific Advisory Board

Retrieved on: 
Monday, July 15, 2019

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box , today announced that it has appointed David A. Judd to PharmaCytes Medical and Scientific Advisory Board.

Key Points: 
  • PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box , today announced that it has appointed David A. Judd to PharmaCytes Medical and Scientific Advisory Board.
  • PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box.
  • PharmaCyte is exploring the use of genetically modified liver cells, stem cells and beta islet cells.
  • More information about PharmaCyte Biotech can be found at www.PharmaCyte.com .